New CEO Revamps Top Team, Specialty Care Business At Sobi
Executive Summary
The new CEO of Sweden's rare diseases company sets up an executive team, highlights its specialty business, and forecasts a better 2017 than previously thought.
You may also be interested in...
Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets
Swedish specialty pharma and rare diseases company seeks to sustain recent rapid revenues growth with increased R&D focus and investments in its hematology and immunology franchises.
Sobi Advances Growth Strategy With Gamifant Launch In Early 2019 For Primary HLH
The interferon gamma blocker is the first new therapy for HLH in 24 years. FDA approval came about four months after Sobi acquired global rights from NovImmune in a deal meant to improve the company's growth prospects.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.